---
title: "Matinas BioPharma soars 32% intraday on heavy volume"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293960783.md"
description: "Matinas BioPharma (MTNB) jumped 32% intraday to $0.32 on volume of 189M shares, following a 78% premarket surge."
datetime: "2026-07-27T17:21:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293960783.md)
  - [en](https://longbridge.com/en/news/293960783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293960783.md)
generator: "portal-rs"
---

# Matinas BioPharma soars 32% intraday on heavy volume

Matinas 生物制药 (MTNB.US) 盘中涨**32.56%**，现报**0.32**美元。

该股 7 月 28 日盘前交易阶段曾大涨超 78%，常规交易时段一度飙升 37% 并触发 5 分钟急涨警报，成交量显著放大至 1.89 亿股。7 月 23 日公司曾公告终止与 Btig 的销售协议，近期无其他明显催化消息。

### Related Stocks

- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)

## Related News & Research

- [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md)
- [D.A. Davidson & CO. Sells 38,578 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/296694848.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?](https://longbridge.com/en/news/296546525.md)
- [Omeros (OMER) Turns Profitable As Fair Value Questions Come Into View](https://longbridge.com/en/news/296706352.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**